Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial

Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.

Actinogen Medical begins landmark Alzheimer’s disease clinical trial

Actinogen Medical (ASX:ACW) has reached a major milestone with the first patient treated in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease.

Actinogen Medical on track to begin Alzheimer’s disease trial

Actinogen Medical (ASX:ACW) has received the approval in the UK to conduct its Phase II clinical trial of Xanamem™ for mild Alzheimer’s disease.

Actinogen Medical in an ASX trading halt

Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.

Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

Actinogen Medical Ltd (ASX:ACW) is making progress in its Phase II clinical trial of its promising new Alzheimer’s drug Xanamem after discussions with the U.S. FDA. The company is seeking FDA approval under an Investigational New Drug (IND) for the Phase II study of the drug. The company is interacting with the U.S. FDA to enhance the safety profile of XanADu, their pivotal global Phase II clinical trial investigating Xanamem.

Appendix 3B


Section 708A Notice


Appendix 4C - quarterly


Appendix 4D & Half Year Report


R&D Rebate


Appendix 4C - quarterly


Appendix 3Y-Dr Bill Ketelbey